Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Cinqair (reslizumab) is indicated for add-on maintenance treatment of patients aged 18 years and older with severe asthma and an eosinophilic phenotype.
• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-8]
• Reslizumab IV significantly reduced clinically significant asthma exacerbations by approximately 50% (Rate ratio: 0.43; 95% CI: 0.33 to 0.55) in patients with severe eosinophilic asthma.
• In real-world settings, reslizumab significantly reduced the annualized exacerbation rate by -6.72 (95% CI: -8.47 to -4.97) and showed improvements in FEV₁ post-treatment.
• Network meta-analysis indicated reslizumab had favorable outcomes compared to mepolizumab, with significant improvements in FEV₁ at 4 weeks and reductions in eosinophil counts at multiple time points (4, 16, and 24 weeks).
• No specific safety outcomes were reported for reslizumab in studies related to quality of life and lung function in severe asthma and CRSwNP, real-world efficacy, and the comparison of monoclonal antibodies.
• Reslizumab did not show an excess of serious adverse events, nor was there a difference in adverse events leading to discontinuation compared to placebo, and no significant safety concerns were observed in comparisons with mepolizumab and benralizumab.
• The population types and subgroups considered in the reviewed studies primarily focus on patients with severe eosinophilic asthma, including adults and children aged 6 to 17 years, as well as patients with combined asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Real-world settings also included diverse participant groups reflective of clinical practice, particularly those with high eosinophil counts. The effectiveness of reslizumab was consistently noted in these populations, with significant reductions in exacerbations and improvements in lung function.